[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"St. Josefs-Hospital Wiesbaden GmbH\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":64},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":5},"100625925","av-node-ablation-and-conduction-system-pacing-for-atrial-fibrillation-with-preserved-left-ventricular-function-100625925",false,"NCT07428967","AV Node Ablation and CONDUCTion System Pacing for Atrial Fibrillation With Preserved Left Ventricular Function","AtrioVentricular Node Ablation and CONDUCTion System Pacing for Atrial Fibrillation With Preserved Left Ventricular Function - a Randomized Controlled Trial","AVA CONDUCT","Inclusion Criteria:\n\n1. History of symptomatic AF (EHRA IIb - IV) despite guideline-indicated medical or interventional therapy\n2. Preserved LVEF (≥ 50%, assessed by echocardiography, Simpson's biplane method)\n3. AV node ablation scheduled independently of possible study participation\n4. Age ≥ 18 years\n5. Consent capacity\n\nExclusion Criteria:\n\n1. Impaired LVEF (\\\u003C 50%)\n2. Pre-implanted pacemaker\n3. Contraindication for pacemaker implantation or AV node ablation (see chapter 5.3 for details)\n4. High grade (III°) left cardiac valvular disease\n5. Surgical coronary revascularization (within the last 30 days) or current triple therapy after stent PCI\n6. Body-mass-index \\> 40 kg\u002Fm2\n7. Pregnancy\n8. Inability to give written informed consent\n9. Life expectancy \\\u003C 12 months","ALL","18 Years",{"count":20,"type":21},86,"ESTIMATED","INTERVENTIONAL",[24],"NA","AVA CONDUCT is a prospective, multicenter, randomized study with single blinding, comparing left bundle branch area (LBBA) pacing with right ventricular (RV) pacing following AV node ablation in terms of clinical, functional, and electrophysiological outcomes.\n\nThe primary hypothesis is that pacing-induced cardiomyopathy, defined as a decrease in LVEF by 10% or more from baseline to an absolute value below 50%, occurs significantly more frequently in patients receiving RV pacing compared with LBBA pacing. Secondarily, LBBA pacing is expected to maintain comparable procedural safety while providing better cardiac function, resulting in improved quality of life and functional capacity compared with conventional RV pacing.",[27,28],"Atrial Fibrillation","Atrial Arrhythmia","RECRUITING","2026-02-17",{"date":32,"type":33},"2026-02-24","ACTUAL",{"date":35,"type":33},"2026-02-01",{"date":37,"type":21},"2029-12-31",{"name":39,"class":40},"St. Josefs-Hospital Wiesbaden GmbH","OTHER",{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":48,"targetDuration":50,"studyType":51,"phases":4,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":63},"100412785","evaluation-of-the-subjectively-perceived-pelvic-floor-function-in-patients-with-gynecological-tumors-and-breast-cancer-under-systemic-tumor-therapy-using-a-validated-questionnaire-100412785","NCT04655066","Evaluation of the Subjectively Perceived Pelvic Floor Function in Patients With Gynecological Tumors and Breast Cancer Under Systemic Tumor Therapy Using a Validated Questionnaire","PANTHERA-Studie \"Pelvic Floor Disorders in Patients Under ANtineoplastic THERApy\"","Inclusion Criteria:\n\n* Breastcancer under tumor therapy\n* Gynecological carcinoma under tumor therapy\n\nExclusion Criteria:\n\n* none",{"count":49,"type":21},200,"3 Years","OBSERVATIONAL","The multimodal therapy of gynecological malignancies and breast cancer often leads to an impairment of the pelvic floor function. This has a major impact on the quality of life of cancer patients. The aim of the study is to record and analyze the potential subjective impairment of the bladder, bowel and sexual function under systemic tumor therapy as well as possible influencing factors by means of validated disease-specific questionnaires. to find possible starting points for the prevention and treatment of the symptoms.",[54],"Pelvic Floor Disorders","2025-09-22",{"date":57,"type":33},"2025-09-23",{"date":59,"type":33},"2018-04-01",{"date":61,"type":21},"2026-12-31",{"name":39,"class":40},1,""]